nifedipine has been researched along with eplerenone in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, H | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aisa, Y; Ikeda, Y; Kato, J; Mori, T; Nakamura, Y; Okamoto, S; Sakurai, M | 1 |
| Chayama, K; Fujii, Y; Fujimura, N; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Iwamoto, Y; Kato, H; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J | 1 |
| Dorrance, AM; Jackson, WF; Pires, PW | 1 |
| Goto, M; Hasebe, N; Takahashi, F; Wada, Y | 1 |
1 review(s) available for nifedipine and eplerenone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for nifedipine and eplerenone
| Article | Year |
|---|---|
Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cell Movement; Endothelium, Vascular; Eplerenone; Female; Humans; Hypertension; Leukocytes; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nifedipine; Nitroglycerin; rho-Associated Kinases; Spironolactone; Stem Cells; Vascular Endothelial Growth Factor A; Vasodilation | 2012 |
5 other study(ies) available for nifedipine and eplerenone
| Article | Year |
|---|---|
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
Topics: Carboxylic Acids; Cytochrome P-450 Enzyme System; Esters; Humans; Hydrolysis; Microsomes; Models, Molecular; Molecular Structure; Prodrugs; Quantum Theory; Signal Transduction | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Hypotension due to the drug interaction of voriconazole with eplerenone and nifedipine.
Topics: Antifungal Agents; Antihypertensive Agents; Drug Interactions; Drug Therapy, Combination; Eplerenone; Humans; Hypotension; Male; Middle Aged; Nifedipine; Pyrimidines; Spironolactone; Triazoles; Voriconazole | 2009 |
Regulation of myogenic tone and structure of parenchymal arterioles by hypertension and the mineralocorticoid receptor.
Topics: Animals; Antihypertensive Agents; Arterioles; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrovascular Circulation; Cerebrum; Compliance; Eplerenone; Hydralazine; Hydrochlorothiazide; Hypertension; Middle Cerebral Artery; Mineralocorticoid Receptor Antagonists; Muscle Tonus; Muscle, Smooth, Vascular; Nifedipine; Organ Size; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Mineralocorticoid; Reserpine; Spironolactone; Vascular Remodeling; Vascular Stiffness | 2015 |
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Creatinine; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hypertension, Malignant; Male; Nifedipine; Nitroglycerin; Obesity; Renal Insufficiency; Spironolactone; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2015 |